• English
  • Korean
  • Chinese
表紙
市場調査レポート - 235095

チェコ共和国の新興医薬品市場:医療改革計画が成長率を低下させる見通し

Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates

発行 GBI Research
出版日 ページ情報 英文 79 Pages
価格
チェコ共和国の新興医薬品市場:医療改革計画が成長率を低下させる見通し Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
出版日: 2012年02月29日 ページ情報: 英文 79 Pages
概要

チェコ共和国の医薬品市場は、中欧・東欧における最も魅力的な市場の一つです。費用対効果の高い熟練労働者の可用性、高品質のインフラ、EUの調和的な規制が、チェコの医薬品業界を急速に成長させている主な要因です。

当レポートでは、チェコ共和国の医薬品市場について調査分析し、業界の動向・問題点・課題を検証し、主要企業の競合情勢、M&Aや戦略的提携の情報なども含めて、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 業界の特徴

  • 市場規模と市場予測
  • 適応別市場シェア
  • ブランド薬とジェネリック薬のシェア
  • 研究開発費の技術革新
  • 大手製薬会社
  • 外国直接投資
  • マーケティング流通経路
  • 輸出入
  • 市場促進要因・抑制要因
  • 業界分析

第4章 マクロ経済環境

  • 人口統計分析
  • GDP
  • 一人当たりの国民所得
  • 医療費
  • 医療インフラ

第5章 医療規制

  • チェコ共和国の薬事規制
  • 知的財産権(IPR)とジェネリック薬の参入
  • 健康保険制度
  • 薬価と償還
  • 新薬承認プロセス
  • 臨床試験
  • 規制機関

第6章 業界の動向

  • M&A
  • ライセンス契約

第7章 CRO業界

  • 臨床試験受託機関(CRO)
  • CRO企業プロファイル:外国企業
    • Quintiles
    • PPD
    • Covance
    • Inc Research
    • PAREXEL
    • Chiltern
    • MEDPACE
    • PRA International
  • CRO企業プロファイル:国内企業
    • CEPHA
    • KCR
    • A-Pharma
    • EastHORN
    • Prague Clinical Services
    • PHARMNET

第8章 付録

図表

目次

Abstract

Summary

The Czech Republic pharmaceutical market is one of the most attractive markets in Central and Eastern Europe. The availability of cost effective skilled labour, high quality infrastructure and EU harmonious regulations are the main reasons for the fast growth of the Czech pharmaceutical industry. Most local drug manufacturers and distributors are owned by big international pharmaceutical firms. GBI Research valued the Czech pharmaceutical market at $3.1 billion in 2010, which grew with a compound annual growth rate (CAGR) of 11.7% from 2004 to 2010. The Czech healthcare sector will witness many new healthcare reforms in the coming years, with the primary objective of reducing growing drug expenditure. In response to these healthcare policies, the Czech pharmaceutical market is expected to witness a lower growth rate in forecast period.

GBI Research has analyzed that in 2011, generics had a share of over 50% of the Czech pharmaceutical market. Czech government reforms encourage the manufacture and use of generic drugs, in an attempt to limit drug expenditure and provide low cost-effective public healthcare. Government healthcare policies, coupled with numerous active generic manufacturing companies in the country, will increase the share of generics in the market during the forecast period.

The Czech Republic is showing a moderate recovery from the economic downturn in 2009; increased industrial outputs and government structural reforms in various sectors including healthcare have contributed to the growth. GBI Research analyzed that the new healthcare reform policy which is expect to be implemented from 2012, with elements of "standard" and "above standard" care, in which patients pay more for above standard (expensive drugs and services) care and an increase in co-payments from the patients, reduces healthcare affordability for individual patients and will pose a major challenge to the Czech pharmaceutical market.

Scope

  • Overall pharma, biotech and outsourcing market structure in Czech Republic
  • Czech Republic pharmaceutical market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights.
  • Czech Republic CRO market growth.
  • Analysis of the leading segments within the Czech Republic pharmaceutical industry.
  • Key market drivers and restraints that have a significant impact on the Czech Republic pharmaceutical market.
  • Competitive benchmarking of leading companies in pharmaceutical and CRO markets.
  • Key M&A activities and strategic partnership deals that have taken place between 2009 and mid 2011.

Reasons to buy

  • Develop market entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers of the country's pharmaceutical market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Executive Summary

GBI Research's new report, “Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates” provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes the overall pharmaceutical and outsourcing market structure in the Czech Republic. Further to this, the report provides competitive benchmarking for leading companies and analyzes the M&A and strategic partnerships that shape the Czech pharmaceutical market. This report is based on data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Antineoplastics and Cardiovascular Drugs Account for Approximately One-Third of the Czech Republic Pharmaceutical Market

The Czech Republic pharmaceutical market is dominated by the sales of antineoplastics and cardiovascular drugs. In 2010, antineoplastics accounted for 19% of drug consumption and cardiovascular drugs, for 15% of drugs consumption. Over the past five years spending on cancer drugs has increased significantly, from 14% in 2006, to 19% in 2010 as a result of the increased prevalence of different types of cancers in the Czech Republic. There are currently 80,000 cancer patients in the Czech Republic and this figure is expected to reach 90,100 by 2018, leading to an increase in antineoplastic drug consumption in the coming years. The other major class of drug, cardiovascular drugs, generated a significant proportion of revenue in the Czech pharmaceutical market.

A non-linear trend has been observed in the consumption of cardiovascular drugs in recent years. In 2010, cardiovascular drug revenues constituted 15% of the pharmaceutical market. Sales of these two major classes of drugs contributed to over one-third of the Czech pharmaceutical market. GBI Research forecasted that the use of these specialized classes of drugs would continue to grow during the forecast period, due to the increasing ageing population in the Czech Republic, who are highly susceptible to various cardiovascular diseases and growing cancer incidence rates.

Introduction of New Healthcare Reform Plans by Czech Government would Regulate Country's Drug Expenditure

The Czech Republic's healthcare system is in transition phase, with new reform packages and amendments. The major issue presented to the Czech government is raising healthcare expenditure which recently surpassed 8% of the country's GDP in 2009. The country faced a major financial crisis in 2009 and in an effort to boost the economy; the Czech Republic introduced many new healthcare reforms to limit the expenditure on healthcare, including spending on both drugs and healthcare services. Growth in drug expenditure was confined to 1.3% in 2010 as a result of a reduction in the prices of drugs and reimbursement levels, both key elements in healthcare plans. The 'Janota package', which led to a drop in prices and reimbursement of drugs by 7%, was one of the other key factors. In 2011, the Czech pharmaceutical industry presented a new healthcare reform to restrict the entry of expensive healthcare into the market by imposing stringent regulatory rules. The Czech government plans to divert spending from expensive equipment and medicines and increase salaries of doctors.

The first phase of healthcare plans in the forecast period would effectively be introduced in January 2012, with key elements such as increasing co-payment from patients and extra fees for above standard care (including expensive drugs). It is uncertain whether the reform would raise healthcare funds because a 4% increase in value added tax (VAT), commencing from 2012, would restrict patient affordability for private care and payments for co-payment.

The second phase is expected to start by 2013, with the main areas of target, healthcare insurance system and long term care. Privatization of healthcare services and the reduction of public health insurance companies will be key elements in future healthcare laws. These reforms are likely to affect the affordability of drugs for individual, and the nature in which healthcare is approached, resulting in the regulation of Czech Republic's pharmaceutical market.

The Generics make over 50% Of the Total Pharmaceutical Market Share in Terms of Value and Is Expected to Grow

The Czech Republic pharmaceutical sector is occupied by generic drugs which currently constitute over 50% of the market in terms of value and is expected to increase further during the forecast period. The Czech Republic is experiencing an influx of emerging generic pharmaceutical companies, alongside already established generic pharmaceutical companies, engaged in the manufacture of API's, pharmaceutical preparations and contract manufacturing services. In 2010, retail sales of generic drugs was valued at $1.7 billion in the Czech Republic and this figure is forecasted to grow at a significant rate, as a result of the implementation of new government policies in coming years. The primary aim of these policies is to reduce drug expenses through various healthcare laws, and in particular, the promotion of generic substitution.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Emerging Pharmaceutical Market - Czech Republic - Introduction

  • 2.1 GBI Research Report Guidance

3. Emerging Pharmaceutical Market - Czech Republic - Industry Characterstics

  • 3.1 Market Size and Market Forecast
  • 3.2 Market Share by Indication
  • 3.3 Branded versus Generic Share
  • 3.4 R&D Expenditure Innovations
  • 3.5 Top Pharmaceutical Companies
  • 3.6 Foreign Direct Investment
  • 3.7 Marketing Distribution Channel
  • 3.8 Exports and Imports
    • 3.8.1 Exports
    • 3.8.2 Imports
  • 3.9 Market Drivers and Restraints
    • 3.9.1 Drivers
    • 3.9.2 Restraints
  • 3.10 Industry Analysis

4. Emerging Pharmaceutical Market - Czech Republic - Macroeconomic Environment

  • 4.1 Demographic Analysis
    • 4.1.1 Population Size, Growth, and Structure
    • 4.1.2 Disease Overview in Czech Republic
  • 4.2 GDP
  • 4.3 Per Capita Income
  • 4.4 Healthcare Expenditure
    • 4.4.1 Context
    • 4.4.2 Analytical Framework
  • 4.5 Healthcare Infrastructure
    • 4.5.1 Context
    • 4.5.2 Analytical Framework

5. Emerging Pharmaceutical Market - Czech Republic - Healthcare Regulation

  • 5.1 Pharmaceutical Regulation in Czech Republic
    • 5.1.1 Healthcare System Structure
    • 5.1.2 Recent Healthcare Reform Plans
  • 5.2 Intellectual property Rights (IPR) and entry of Generics
  • 5.3 Health Insurance Coverage
    • 5.3.1 Public Insurance Coverage
    • 5.3.2 Private Insurance Coverage
  • 5.4 Pricing and Reimbursement
    • 5.4.1 Pricing
    • 5.4.2 Reimbursement
  • 5.5 New Drug Approval Process
  • 5.6 Clinical Trials
  • 5.7 Regulatory Bodies

6. Emerging Pharmaceutical Market - Czech Republic - Industry Trends

  • 6.1 Mergers and Acquisitions
    • 6.1.1 Deals by Year
    • 6.1.2 Deals by Type
    • 6.1.3 Deal by Value
    • 6.1.4 Top M&A Deals
  • 6.2 Licensing Agreements
    • 6.2.1 Deals by Year
    • 6.2.2 Top Three Licensing Deals

7. Emerging Pharmaceutical Market - Czech Republic - CRO Industry

  • 7.1 Clinical Research Organization (CRO)
  • 7.2 CRO Company Profiles - Foreign Players
    • 7.2.1 Quintiles
    • 7.2.2 PPD
    • 7.2.3 Covance
    • 7.2.4 Inc Research
    • 7.2.5 PAREXEL
    • 7.2.6 Chiltern
    • 7.2.7 MEDPACE
    • 7.2.8 PRA International
  • 7.3 CRO Company Profiles - Domestic Players
    • 7.3.1 CEPHA
    • 7.3.2 KCR
    • 7.3.3 A-Pharma
    • 7.3.4 EastHORN
    • 7.3.5 Prague Clinical Services
    • 7.3.6 PHARMNET

8. Emerging Pharmaceutical Market - Czech Republic - Appendix

  • 8.1 Market Definitions
  • 8.2 Abbreviations
  • 8.3 Research Methodology
    • 8.3.1 Industry Performance
    • 8.3.2 Macroeconomic Environment
    • 8.3.3 Healthcare Regulations
    • 8.3.4 Industry Trends
  • 8.4 Contact Us
  • 8.5 Disclaimer
  • 8.6 Sources

List of Tables

  • Table 1: Emerging Pharmaceutical Market - Czech Republic, Revenue, $bn, 2004 - 2010
  • Table 2: Emerging Pharmaceutical Market - Czech Republic, Revenue Forecast, $bn, 2010 - 2018
  • Table 3: Emerging Pharmaceutical Market - Czech Republic, Government Budget Expenditure on Healthcare R&D, $m, 2004-2010
  • Table 4: Emerging Pharmaceutical Market - Czech Republic, Pharmaceutical Companies' Expenditure on R&D, $m, 2003-2009
  • Table 5: Emerging Pharmaceutical Market - Czech Republic, FDI Inflows and Outflows for Pharmaceuticals and related Medicinal Chemicals, $m, 2004-2009
  • Table 6: Emerging Pharmaceutical Market - Czech Republic, Number of Pharmacies and Outlets, 2004-2010
  • Table 7: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Exports, $m, 2004- 2010
  • Table 8: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Imports, $m, 2004- 2010
  • Table 9: Emerging Pharmaceutical Market - Czech Republic, Population Forecast of Czech Republic ,Thousands, 2005 - 2050
  • Table 10: Emerging Pharmaceutical Market - Czech Republic, Population by Gender, Thousands, 2000 - 2009
  • Table 11: Emerging Pharmaceutical Market - Czech Republic, Infant Mortality Rate (Number of deaths/1,000 live births) 2000 - 2010
  • Table 12: Emerging Pharmaceutical Market - Czech Republic, Number of Deaths by Major Diseases (%), 2010
  • Table 13: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cardiovascular Diseases ('000), 2010-2018
  • Table 14: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cancer ('000), 2010-2018
  • Table 15: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Respiratory Diseases ('000), 2010-2018
  • Table 16: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Diabetes ('000), 2010-2018
  • Table 17: Emerging Pharmaceutical Market - Czech Republic, GDP at Market Prices, $bn, 2005-2010
  • Table 18: Emerging Pharmaceutical Market - Czech Republic, GDP Growth Rate and Inflation Rates in Czech Republic, 2005-2010
  • Table 19: Emerging Pharmaceutical Market - Czech Republic, Per Capita Income, $, 2000 - 2010
  • Table 20: Emerging Pharmaceutical Market - Czech Republic, Healthcare Expenditure, $bn, 2000-2010
  • Table 21: Emerging Pharmaceutical Market - Czech Republic, Comparative Government and Private Healthcare Expenditure, 2000 - 2008
  • Table 22: Emerging Pharmaceutical Market - Czech Republic, Comparative Healthcare Expenditure, 2000 - 2008
  • Table 23: Emerging Pharmaceutical Market - Czech Republic, Healthcare Establishments Distribution (%), 2010
  • Table 24: Emerging Pharmaceutical Market - Czech Republic, Public and Private Healthcare Establishments and Professionals Distribution, %, 2010
  • Table 25: Emerging Pharmaceutical Market - Czech Republic, Bed Distribution in Healthcare Establishments, Czech Republic (%), 2010
  • Table 26: Emerging Pharmaceutical Market - Czech Republic, Health Insurance Coverage on Healthcare Expenditure, $m, 2006- 2010
  • Table 27: Emerging Pharmaceutical Market - Czech Republic, Deals Landscape, M&A Deals, 2011
  • Table 28: Emerging Pharmaceutical Market - Czech Republic, Licensing Deals by Year, 2011

List of Figures

  • Figure 1: Emerging Pharmaceutical Market - Czech Republic, Revenue Forecast, $bn, 2004 - 2018
  • Figure 2: Emerging Pharmaceutical Market - Czech Republic, Market Share by Therapy Area(%), 2010
  • Figure 3: Emerging Pharmaceutical Market - Czech Republic, Branded versus Generic Share in Terms of Value(%), 2010
  • Figure 4: Emerging Pharmaceutical Market - Czech Republic, Government Budget Expenditure on Healthcare R&D, $m, 2004-2010
  • Figure 5: Emerging Pharmaceutical Market - Czech Republic, Pharmaceutical Companies' Expenditure on R&D, $m, 2003-2009
  • Figure 6: Emerging Pharmaceutical Market - Czech Republic, Number of Pharmacies and Outlets, 2004-2010
  • Figure 7: Emerging Pharmaceutical Market - Czech Republic, Distribution of Pharmacies by Owner (%), 2010
  • Figure 8: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Exports, $m, 2004- 2010
  • Figure 9: Emerging Pharmaceutical Market - Czech Republic, Medicinal and Pharmaceutical Products Imports, $m, 2004- 2010
  • Figure 10: Emerging Pharmaceutical Market - Czech Republic, Market Drivers, 2011
  • Figure 11: Emerging Pharmaceutical Market - Czech Republic, Market Restraints, 2011
  • Figure 12: Emerging Pharmaceutical Market - Czech Republic, Industry Analysis, 2011
  • Figure 13: Emerging Pharmaceutical Market - Czech Republic, Population Age Structure Forecast of Czech Republic ,Thousands, 2005 - 2050
  • Figure 14: Emerging Pharmaceutical Market - Czech Republic, Population by Gender, Thousands, 2000 - 2009
  • Figure 15: Emerging Pharmaceutical Market - Czech Republic, Life Expectancy, Years, 2000 - 2010
  • Figure 16: Emerging Pharmaceutical Market - Czech Republic, Infant Mortality Rate (Number of deaths/1,000 live births) 2000 - 2010
  • Figure 17: Emerging Pharmaceutical Market - Czech Republic, Number of Deaths by Major Diseases (%), 2010
  • Figure 18: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cardiovascular Diseases ('000), 2010-2018
  • Figure 19: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Cancer ('000), 2010-2018
  • Figure 20: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Respiratory Diseases ('000), 2010-2018
  • Figure 21: Emerging Pharmaceutical Market - Czech Republic, Population Forecast for Diabetes ('000), 2010-2018
  • Figure 22: Emerging Pharmaceutical Market - Czech Republic, GDP at Market Prices, $bn, 2005-2010
  • Figure 23: Emerging Pharmaceutical Market - Czech Republic, GDP Composition by Sector, 2010
  • Figure 24: Emerging Pharmaceutical Market - Czech Republic, GDP and Inflation Rates in Czech Republic, 2005 - 2011
  • Figure 25: Emerging Pharmaceutical Market - Czech Republic, Average Exchange Rates, CZK, 2005 - 2011
  • Figure 26: Emerging Pharmaceutical Market - Czech Republic, Per Capita Income, $, 2000 - 2010
  • Figure 27: Emerging Pharmaceutical Market - Czech Republic, National Healthcare Expenditure, % of GDP, 2010
  • Figure 28: Emerging Pharmaceutical Market - Czech Republic, Healthcare Expenditure, $bn, 2000-2010
  • Figure 29: Emerging Pharmaceutical Market - Czech Republic, Healthcare Establishments Distribution (%), 2010
  • Figure 30: Emerging Pharmaceutical Market - Czech Republic, Public and Private Healthcare Establishments and Professionals Distribution, %, 2010
  • Figure 31: Emerging Pharmaceutical Market - Czech Republic, Healthcare Professionals, Czech Republic (%), 2010
  • Figure 32: Emerging Pharmaceutical Market - Czech Republic, Bed Care in Hospitals by Department, %, 2010
  • Figure 33: Emerging Pharmaceutical Market - Czech Republic, Health Insurance Coverage on Healthcare Expenditure, $m, 2006- 2010
  • Figure 34: Emerging Pharmaceutical Market - Czech Republic, Clinical Trials and New Drug Approval Process,2011
  • Figure 35: Emerging Pharmaceutical Market - Czech Republic, Clinical Trial Applications Assessed by Phase (%), 2010
  • Figure 36: Emerging Pharmaceutical Market - Czech Republic, Clinical Trials Assessed by Therapeutic Areas (%), 2010
  • Figure 37: Emerging Pharmaceutical Market - Czech Republic, Regulatory authorities of State Institute for Drug Control, Czech Republic.
  • Figure 38: Emerging Pharmaceutical Market - Czech Republic, M&A Deals by Year, 2009 - 2011
  • Figure 39: Emerging Pharmaceutical Market - Czech Republic, M&A Deals by Type, 2009 - 2011
  • Figure 40: Emerging Pharmaceutical Market - Czech Republic, Acquisition Deals by Type, 2009 - 2011
  • Figure 41: Emerging Pharmaceutical Market - Czech Republic, M&A Deals by Value, $m, 2009 - 2011
  • Figure 42: Emerging Pharmaceutical Market - Czech Republic, Licensing Deals by Year, 2009 - 2011
  • Figure 43: Emerging Pharmaceutical Market - Czech Republic, Quintiles, Company Profile, 2011
  • Figure 44: Emerging Pharmaceutical Market - Czech Republic, PPD, Company Profile, 2011
  • Figure 45: Emerging Pharmaceutical Market - Czech Republic, Covance, Company Profile, 2011
  • Figure 46: Emerging Pharmaceutical Market - Czech Republic, INC Research, Company Profile, 2011
  • Figure 47: Emerging Pharmaceutical Market - Czech Republic, PARAXEL, Company Profile, 2011
  • Figure 48: Emerging Pharmaceutical Market - Czech Republic, Chiltren, Company Profile, 2011
  • Figure 49: Emerging Pharmaceutical Market - Czech Republic, MEDPACE, Company Profile, 2011
  • Figure 50: Emerging Pharmaceutical Market - Czech Republic, Pra, Company Profile, 2011
  • Figure 51: Emerging Pharmaceutical Market - Czech Republic, CEPHA, Company Profile, 2011
  • Figure 52: Emerging Pharmaceutical Market - Czech Republic, KCR, Company Profile, 2011
  • Figure 53: Emerging Pharmaceutical Market - Czech Republic, A-pharma, Company Profile, 2011
  • Figure 54: Emerging Pharmaceutical Market - Czech Republic, EastHORN, Company Profile, 2011
  • Figure 55: Emerging Pharmaceutical Market - Czech Republic, Prague Clinical Services, Company Profile, 2011
  • Figure 56: Emerging Pharmaceutical Market - Czech Republic, PHARMNET, Company
Back to Top